Table 2.

Trials with drugs targeting KRAS mutations.

KRAS	Cyclophosphamide-fludarabine then mutant KRAS G12V-specific TCR transduced autologous T cells ± anti-PD1	I/II	NCT04146298
ERK	Ulixertinib (BVD-523) is an oral, first-in-class ERK1/2 inhibitor	I	NCT04566393
KRAS	HBI-2376 = SHP2 inhibitor in advanced malignant solid tumors harboring KRAS or EGFR mutations	I	NCT05163028
KRAS	NBF-006: lyophilized lipid nanoparticle with encapsulated siRNA	I	NCT03819387
KRAS	Mesenchymal stromal cells-derived exosomes with KrasG12D siRNA	I	NCT03608631
KRAS	ELI-002 2P (lipid-conjugated immune-stimulatory oligonucleotide [Amph-CpG-7909] plus a mixture)	I	NCT04853017
KRAS-ERK	JAB-3312: inhibitor of Src homology 2 domain-containing phosphatase (SHP2)	I	NCT04121286
KRASG12C	LY3537982 combined with several agent in KRAS G12C-mutant tumors	I	NCT04956640
KRASG12C	Adagrasib in combination with BI 1701963 (SOS1 inhibitor) (KRYSTAL 14)	I	NCT04975256
KRASG12C	GDC-6036 combined with atezolizumab, cetuximab, bevacizumab, erlotinib	Ia/Ib	NCT04449874
KRASG12C	JDQ443 monotherapy and combined with TNO155 and spartalizumab	Ib/II	NCT04699188
KRASG12D	PBL transduced with a murine TCR against G12D variant of mutated RAS in HLA-A*11:01 patients	I/II	NCT03745326
KRASG12V	PBL transduced with a murine TCR against G12V variant of mutated RAS in HLA-A*11:01 patients	I/II	NCT03190941

ERK, extracellular signal-regulated kinase; HLA, human leukocyte antigen; TCRs, T-cell receptors.